Often called the silent thief of sight, glaucoma is a group of eye diseases that gradually damage the optic nerve, often without warning signs. It is linked to increased pressure (ocular hypertension) inside the eye and, if left untreated, can lead to permanent vision loss. Even with ongoing treatment, some people still face the risk of progressive vision loss.

This led scientists to look for newer therapeutics that can help manage the disease’s progression, such as nicotinamide, a form of vitamin B3.

In a recent study, researchers conducted a large-scale data analysis to investigate whether nicotinamide could help prevent or delay the onset of primary open-angle glaucoma (POAG) in high-risk patients.